MY122216A - New vaccine and method of use - Google Patents
New vaccine and method of useInfo
- Publication number
- MY122216A MY122216A MYPI99003916A MYPI9903916A MY122216A MY 122216 A MY122216 A MY 122216A MY PI99003916 A MYPI99003916 A MY PI99003916A MY PI9903916 A MYPI9903916 A MY PI9903916A MY 122216 A MY122216 A MY 122216A
- Authority
- MY
- Malaysia
- Prior art keywords
- vaccine
- transmitted diseases
- prevention
- treatment
- adjuvant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 208000019802 Sexually transmitted disease Diseases 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 abstract 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9819898A GB9819898D0 (en) | 1998-09-11 | 1998-09-11 | New vaccine and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY122216A true MY122216A (en) | 2006-03-31 |
Family
ID=10838766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99003916A MY122216A (en) | 1998-09-11 | 1999-09-09 | New vaccine and method of use |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1109574B1 (https=) |
| JP (1) | JP2002524532A (https=) |
| KR (1) | KR100777896B1 (https=) |
| CN (2) | CN1325311A (https=) |
| AR (1) | AR021798A1 (https=) |
| AT (1) | ATE392214T1 (https=) |
| AU (1) | AU744989B2 (https=) |
| BR (1) | BR9913630A (https=) |
| CA (1) | CA2343399C (https=) |
| CO (1) | CO5090882A1 (https=) |
| CY (1) | CY1108147T1 (https=) |
| CZ (1) | CZ302808B6 (https=) |
| DE (1) | DE69938555T2 (https=) |
| DK (1) | DK1109574T3 (https=) |
| ES (1) | ES2304068T3 (https=) |
| GB (1) | GB9819898D0 (https=) |
| HU (1) | HUP0104297A3 (https=) |
| IL (1) | IL141843A0 (https=) |
| MY (1) | MY122216A (https=) |
| NO (1) | NO329522B1 (https=) |
| NZ (1) | NZ510425A (https=) |
| PL (1) | PL199545B1 (https=) |
| PT (1) | PT1109574E (https=) |
| SI (1) | SI1109574T1 (https=) |
| TR (1) | TR200100948T2 (https=) |
| TW (1) | TWI225790B (https=) |
| WO (1) | WO2000015255A1 (https=) |
| ZA (1) | ZA200101987B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
| GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2011008400A2 (en) | 2009-06-16 | 2011-01-20 | Novartis Ag | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| AU2011237393B2 (en) | 2010-04-08 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| CA2843854A1 (en) | 2011-07-01 | 2013-01-10 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
| US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| JP7525976B2 (ja) * | 2014-07-07 | 2024-07-31 | エリアン リミテッド ライアビリティ カンパニー | ウイルス予防治療方法及び曝露前予防キット |
| BR112018017141A2 (pt) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | método para a imobilização de biomoléculas |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| ATE157882T1 (de) * | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| GB9506863D0 (en) * | 1995-04-03 | 1995-05-24 | Smithkline Beecham Biolog | Vaccines |
-
1998
- 1998-09-11 GB GB9819898A patent/GB9819898D0/en not_active Ceased
-
1999
- 1999-09-08 CN CN99813127A patent/CN1325311A/zh active Pending
- 1999-09-08 SI SI9931008T patent/SI1109574T1/sl unknown
- 1999-09-08 HU HU0104297A patent/HUP0104297A3/hu unknown
- 1999-09-08 CN CNA2007101469740A patent/CN101130070A/zh active Pending
- 1999-09-08 ES ES99969034T patent/ES2304068T3/es not_active Expired - Lifetime
- 1999-09-08 CZ CZ20010887A patent/CZ302808B6/cs not_active IP Right Cessation
- 1999-09-08 JP JP2000569839A patent/JP2002524532A/ja active Pending
- 1999-09-08 AU AU59752/99A patent/AU744989B2/en not_active Ceased
- 1999-09-08 KR KR1020017003161A patent/KR100777896B1/ko not_active Expired - Fee Related
- 1999-09-08 PL PL346651A patent/PL199545B1/pl not_active IP Right Cessation
- 1999-09-08 AT AT99969034T patent/ATE392214T1/de active
- 1999-09-08 BR BR9913630A patent/BR9913630A/pt not_active Application Discontinuation
- 1999-09-08 EP EP99969034A patent/EP1109574B1/en not_active Expired - Lifetime
- 1999-09-08 CA CA 2343399 patent/CA2343399C/en not_active Expired - Fee Related
- 1999-09-08 NZ NZ51042599A patent/NZ510425A/xx not_active IP Right Cessation
- 1999-09-08 PT PT99969034T patent/PT1109574E/pt unknown
- 1999-09-08 IL IL14184399A patent/IL141843A0/xx not_active IP Right Cessation
- 1999-09-08 WO PCT/EP1999/006623 patent/WO2000015255A1/en not_active Ceased
- 1999-09-08 DE DE1999638555 patent/DE69938555T2/de not_active Expired - Lifetime
- 1999-09-08 DK DK99969034T patent/DK1109574T3/da active
- 1999-09-08 TR TR200100948T patent/TR200100948T2/xx unknown
- 1999-09-09 AR ARP990104534 patent/AR021798A1/es unknown
- 1999-09-09 MY MYPI99003916A patent/MY122216A/en unknown
- 1999-09-10 CO CO99057608A patent/CO5090882A1/es unknown
- 1999-09-14 TW TW88115828A patent/TWI225790B/zh not_active IP Right Cessation
-
2001
- 2001-03-08 NO NO20011193A patent/NO329522B1/no not_active IP Right Cessation
- 2001-03-09 ZA ZA200101987A patent/ZA200101987B/en unknown
-
2008
- 2008-06-18 CY CY081100643T patent/CY1108147T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY122216A (en) | New vaccine and method of use | |
| HUP9801560A1 (hu) | Szaponint és szterint tartalmazó vakcinák | |
| PT1296711E (pt) | E7 de vph para o tratamento do virus do papiloma humano | |
| AU4358801A (en) | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| NZ287385A (en) | Antigenic preparation comprising the catalase of helicobacter bacteria and vaccines used to treat helicobacter infection | |
| KR970701209A (ko) | 헬리코박터 감염의 치료 또는 예방용 항원제제(antigenic preparation for treatment or prevention of helicobacter infection) | |
| CA2022420A1 (en) | Escherichia coli vaccine | |
| AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
| EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
| EP1305042A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS | |
| SE9401620L (sv) | Kombinerad användning av lokalbedövningsmedel och täckande förband | |
| PL348828A1 (en) | New cancer treatments | |
| EP0955366A4 (en) | ANTIGENIC PROTEIN FROM MALASSEZIA | |
| NZ512850A (en) | Treatment of papillomavirus infections | |
| HUP9901299A2 (hu) | Attenuált, nemimmunogén poxvírusokból vagy parapoxvírusokból előállított multipotens parapox immunitást előidéző gyógyszerek használatának új indikációi | |
| BR0011478A (pt) | Composição de combinação imunológica, métodos de induzir uma resposta imunológica em um animal, e de imunizar um hospedeiro contra infecção pneumocócica, e, composição imunogênica para administração intranasal | |
| ES2158857T3 (es) | Vacunas a base de estreptoquinasa. | |
| BR9809426A (pt) | Composição de vacina anti-helicobacter para uso pela via sistêmica subdiafragmática e método de imunização mucosal/parenteral combinado | |
| BR0210875A (pt) | Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes | |
| BR9805106A (pt) | Processo terapêutico para obtenção e uso de compostos indicados para infecção. | |
| MD2491F1 (en) | Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment | |
| UA49145A (uk) | Спосіб стандартизації моделювання проникної інфікованої травми заднього сегмента ока | |
| UA36840A (uk) | Спосіб лікування хронічних гепатитів різного генезу | |
| UA37909A (uk) | Спосіб діагностики супутньої інфекції у хворих на сифіліс |